INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 12, Issue 9- 2025

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.09.002

Blood Counts and Beyond: Haematological Complications in Cervical Cancer Therapy

*Emmanuel Ifeanyi Obeagu
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Copyright © 2025. Emmanuel Ifeanyi Obeagu This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cervical cancer remains a major global health challenge, with treatment advances improving survival yet often accompanied by significant hematological complications. Therapeutic modalities such as chemotherapy, radiotherapy, and concurrent chemoradiotherapy disrupt hematopoiesis and contribute to anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, and in severe cases pancytopenia. These complications compromise treatment adherence, increase infection and bleeding risks, impair quality of life, and may worsen survival outcomes. The underlying mechanisms include direct bone marrow suppression, chronic tumor-related blood loss, immune dysregulation, and nutritional deficiencies, particularly in resource-limited settings. This review synthesizes current evidence on the biological basis, clinical spectrum, and management of hematological toxicities in cervical cancer therapy. It highlights the importance of routine hematologic monitoring, early supportive interventions, and personalized treatment strategies to minimize adverse effects while preserving therapeutic efficacy. Addressing these challenges is critical to improving both survival and quality of life in women undergoing cervical cancer treatment.

Keywords: Cervical cancer, Hematological complications, Chemoradiotherapy, Anemia, Bone marrow suppression

© 2025, IJCRCPS. All Rights Reserved

Introduction

Cervical cancer is one of the most common gynecological malignancies worldwide and remains a leading cause of cancer-related mortality among women, particularly in low- and middle-income countries [1-2]. Despite significant advances in prevention strategies such as HPV vaccination and cervical cancer screening, many women are still diagnosed at advanced stages of the disease. In such cases, therapeutic approaches including chemotherapy, radiotherapy, and concurrent chemoradiotherapy remain the cornerstone of management, offering improved survival outcomes. However, these treatments are associated with profound systemic toxicities, of which hematological complications are among the most frequent and clinically significant [3-4].Hematological complications in cervical cancer therapy encompass a broad spectrum of abnormalities affecting red blood cells, white blood cells, and platelets [5]. These include anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, and in severe cases, pancytopenia. Such complications not only compromise the patient's ability to tolerate treatment but also lead to interruptions, dose reductions, or even discontinuation of therapy. Consequently, hematological toxicities directly influence treatment efficacy, quality of life, and long-term survival outcomes [6-7].

The biological underpinnings of these complications are multifactorial. While advanced cervical cancer itself may lead to chronic anemia through abnormal uterine bleeding and systemic inflammation, treatment modalities further exacerbate these disturbances. Chemotherapy agents, particularly cisplatin-based regimens, exert cytotoxic effects on rapidly dividing cells, including bone marrow precursors, thereby suppressing hematopoiesis. Radiotherapy directed at the pelvic region damages hematopoietic stem cells in pelvic bones, leading to sustained marrow suppression. When chemotherapy and radiotherapy are administered concurrently, their synergistic toxicities markedly increase the risk of severe hematological derangements [8].Beyond direct myelosuppression, immune dysregulation and nutritional deficiencies play crucial roles in the development of hematological complications. Lymphopenia, a common outcome of pelvic radiotherapy, significantly impairs antitumor immunity and predisposes patients to opportunistic infections. Nutritional deficiencies, particularly iron, folate, and vitamin B12 deficiencies, are highly prevalent among women in resource-limited settings and further exacerbate anemia and other cytopenias. The complex interplay of these factors underscores the systemic burden imposed on patients undergoing cervical cancer therapy [9-10].

The clinical implications of hematological complications extend far beyond laboratory abnormalities. Anemia, for instance, reduces tissue oxygenation and has been associated with poor tumor radiosensitivity and inferior survival outcomes. Neutropenia and lymphopenia predispose patients to recurrent infections, sepsis, and treatment delays, while thrombocytopenia increases bleeding risks and necessitates transfusion support. Pancytopenia, though less common, poses life-threatening risks and often requires prolonged hospitalization. Collectively, these complications exert a heavy toll on patient well-being, healthcare resources, and overall treatment outcomes [11-13].Effective management of hematological complications requires a comprehensive and proactive approach. Supportive strategies such as blood transfusions, iron supplementation, erythropoiesis-stimulating agents, and colony-stimulating factors are commonly employed to restore hematologic balance. Regular monitoring of hematologic parameters during treatment allows for timely interventions, while treatment modifications and emerging bone marrow-sparing techniques offer additional avenues to mitigate toxicity. Nevertheless, the availability and accessibility of supportive care remain highly variable across different healthcare systems, particularly in low-resource settings where the cervical cancer burden is highest [14].

© 2025, IJCRCPS. All Rights Reserved

Biological Basis of Hematological Complications in Cervical Cancer Therapy

The hematological complications observed in cervical cancer therapy arise from a complex interplay of disease-related and treatment-related mechanisms. Cervical cancer itself contributes significantly to hematologic disruption. Chronic abnormal vaginal bleeding, a hallmark of advanced disease, frequently results in iron deficiency anemia. Beyond blood loss, the tumor microenvironment generates a pro-inflammatory milieu, releasing cytokines such as interleukin-6 and tumor necrosis factor-α, which interfere with erythropoiesis and promote anemia of chronic disease. These inflammatory pathways not only suppress red blood cell production but also alter iron metabolism, leading to functional iron deficiency [15-16].Chemotherapy remains a cornerstone in cervical cancer management, with cisplatin-based regimens being the standard of care. However, chemotherapy exerts cytotoxic effects indiscriminately on rapidly dividing cells, including those within the bone marrow. This leads to myelosuppression, manifesting as anemia, neutropenia, thrombocytopenia, or even pancytopenia. The severity of hematologic toxicity often correlates with cumulative dosing and treatment intensity. Chemotherapy also induces oxidative stress and mitochondrial injury within hematopoietic progenitor cells, further impairing marrow recovery [17-18].

Radiotherapy, particularly pelvic irradiation, adds another layer of hematological burden. The pelvic bones contain a significant proportion of active bone marrow, and radiation exposure results in direct DNA damage and apoptosis of hematopoietic stem cells. Over time, this marrow suppression compromises the regeneration of all blood cell lineages. Moreover, radiation-induced vascular injury disrupts the supportive bone marrow microenvironment, compounding hematopoietic impairment. Patients receiving concurrent chemoradiotherapy experience amplified toxicity due to the synergistic effects of chemotherapy and radiation on marrow function [19-20].

Immune dysregulation is another important biological pathway. Lymphopenia, commonly seen after pelvic radiotherapy, stems from both direct lymphocyte depletion and impaired lymphoid organ function. This reduction in immune cell populations compromises antitumor immunity, increasing susceptibility to infections and potentially influencing disease progression. Persistent lymphopenia has been linked to poorer treatment responses and survival outcomes, underscoring its biological and clinical relevance [21-22].Nutritional deficiencies also contribute significantly to hematological complications. Women with cervical cancer, particularly in low-resource settings, often present with pre-existing deficiencies in iron, folate, and vitamin B12. These deficiencies not only exacerbate anemia but also impair the synthesis and maturation of hematopoietic cells. The combination of nutritional inadequacy with aggressive therapy magnifies the risk of hematological toxicities [23].

Spectrum of Hematological Complications

The hematological complications encountered during cervical cancer therapy span a wide range of abnormalities, reflecting the multifactorial impact of disease progression, cytotoxic drugs, and radiotherapy. These complications affect all three major blood cell lineages—erythrocytes, leukocytes, and platelets—manifesting clinically as anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, or, in severe cases, pancytopenia. Each of these conditions carries unique biological underpinnings and clinical consequences that together shape treatment outcomes and patient quality of life [24-25].Anemia remains the most prevalent hematological abnormality in cervical cancer patients. Its origins are diverse, encompassing chronic tumor-related blood loss, nutritional deficiencies, inflammation-driven suppression of erythropoiesis, and direct myelosuppressive effects of therapy. Anemia significantly reduces tissue oxygenation, which compromises tumor radiosensitivity and lowers treatment response rates. Patients often present with fatigue, dyspnea,

© 2025, IJCRCPS. All Rights Reserved

and diminished functional capacity, all of which undermine treatment adherence and overall well-being [8].

Leukopenia and neutropenia frequently develop during chemotherapy, especially with cisplatin-based regimens. Neutropenia poses a particular threat as it predisposes patients to life-threatening infections, often presenting with neutropenic fever that requires urgent hospitalization and intravenous antibiotic therapy. Treatment delays or dose reductions necessitated by neutropenia directly diminish the intensity of therapy, thereby affecting disease control and survival outcomes [26-27].Lymphopenia is another critical complication, especially in patients undergoing pelvic radiotherapy or chemoradiotherapy. Lymphocytes are highly radiosensitive, and their depletion impairs both innate and adaptive immune responses. Persistent lymphopenia weakens antitumor immunity, increasing vulnerability to opportunistic infections and potentially influencing long-term tumor control. Evidence increasingly links post-therapy lymphopenia with poorer progression-free and overall survival, highlighting its prognostic significance [28-30].

Thrombocytopenia, though less common than anemia and neutropenia, is clinically significant when it occurs. It arises from chemotherapy-induced suppression of megakaryocyte precursors and, in some cases, radiation damage to marrow niches. Low platelet counts increase bleeding risks, ranging from mucosal hemorrhage to life-threatening intracranial or gastrointestinal bleeding. Severe thrombocytopenia often necessitates platelet transfusions and may interrupt treatment schedules, adding further complexity to patient management [31-32].In the most severe scenarios, patients may develop pancytopenia, where all three blood cell lines are depleted. This complication typically reflects profound bone marrow suppression due to combined chemotherapy and radiotherapy. Pancytopenia places patients at exceptionally high risk of infection, bleeding, and debilitating fatigue, frequently requiring hospitalization, transfusion support, and intensive monitoring. The occurrence of pancytopenia often forces treatment interruption or termination, compromising cancer control [31].

Clinical Implications and Management

The hematological complications that arise during cervical cancer therapy carry profound clinical implications, often determining the success or failure of treatment plans. These complications not only compromise treatment delivery but also increase morbidity and mortality, emphasizing the need for vigilant monitoring and timely interventions. Their effects extend beyond transient laboratory abnormalities, influencing therapeutic efficacy, patient survival, and overall quality of life [8].Anemia, for example, diminishes tumor radiosensitivity due to inadequate oxygen delivery to tissues. This undermines the effectiveness of radiotherapy and chemoradiotherapy, both of which rely on well-oxygenated tumor cells to achieve optimal cytotoxic effects. Clinically, patients with anemia experience fatigue, breathlessness, and reduced functional capacity, which may impair adherence to demanding treatment schedules. Transfusion support, iron supplementation, and the use of erythropoiesis-stimulating agents are common interventions, although their availability varies across healthcare settings [33].

Leukopenia and neutropenia represent particularly dangerous complications, as they expose patients to infections that can rapidly become life-threatening. Neutropenic fever is a medical emergency that often requires hospitalization, broad-spectrum antibiotics, and treatment delays until marrow recovery. Granulocyte colony-stimulating factors (G-CSF) have proven effective in reducing the incidence and duration of neutropenia, allowing patients to maintain treatment intensity. However, the cost and limited accessibility of these agents remain barriers in many low-resource regions where cervical cancer prevalence is highest [34-35].Lymphopenia, though sometimes overlooked, carries significant implications for both infection risk and cancer control. Prolonged depletion of lymphocyte populations undermines immune surveillance,

© 2025, IJCRCPS. All Rights Reserved

increasing vulnerability to opportunistic infections and potentially reducing the effectiveness of immune-mediated tumor eradication. While no standardized interventions for radiation-induced lymphopenia exist, strategies such as bone marrow-sparing radiotherapy and treatment optimization are being explored to preserve immune competence during therapy [36-37].

Thrombocytopenia poses unique challenges due to bleeding risks, which range from minor mucosal hemorrhage to life-threatening events. Severe thrombocytopenia often necessitates platelet transfusion, but resource constraints may limit access in many settings. Preventive measures, including dose modification of chemotherapy and careful monitoring of platelet counts, are critical in minimizing risk [38].In the most severe cases, pancytopenia emerges as a cumulative consequence of combined chemoradiotherapy. This condition often necessitates prolonged hospitalization, broad supportive care, and transfusion support, with significant implications for healthcare resource allocation. Pancytopenia frequently results in treatment delays or discontinuation, highlighting the delicate balance between achieving tumor control and preserving bone marrow function [39].The management of these complications demands an integrated and proactive approach. Routine hematological monitoring before, during, and after therapy is essential for early detection and timely intervention. Supportive care strategies, including transfusions, growth factors, nutritional supplementation, and infection prophylaxis, form the backbone of management. At the same time, research into less toxic regimens, personalized dosing strategies, and advanced radiotherapy techniques offers promise in reducing hematological toxicity [40].

Conclusion

Hematological complications remain a central challenge in the management of cervical cancer, arising from both disease-related factors and the cytotoxic effects of therapy. Anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia, and pancytopenia each exert unique and overlapping impacts that compromise treatment delivery, increase infection and bleeding risks, and reduce quality of life. Their occurrence often necessitates dose modifications, treatment delays, or discontinuation, thereby diminishing therapeutic efficacy and survival outcomes.Effective management requires a proactive and integrative approach that prioritizes regular hematologic monitoring, early supportive interventions, and personalized treatment strategies. Supportive measures such as transfusions, hematopoietic growth factors, nutritional supplementation, and optimized treatment regimens play an essential role in minimizing morbidity while maintaining treatment intensity.

References

1. Hull, R., Mbele, M., Makhafola, T., Hicks, C., Wang, S. M., Reis, R. M., Mehrotra, R., Mkhize-Kwitshana, Z., Kibiki, G., Bates, D. O., & Dlamini, Z. (2020). Cervical cancer in low and middle-income countries. *Oncology letters*, *20*(3), 2058–2074. https://doi.org/10.3892/ol.2020.11754
2. Luwen, G., Hameed, H., Aslam, B., Liyan, Z., Jabbar, A., &Syyam, A. (2025). Understanding of cervical cancer, human papillomavirus (HPV) and HPV vaccine among women from Pakistan and Afghanistan. *Ecancermedical science*, *19*, 1891. https://doi.org/10.3332/ecancer.2025.1891
3. Obeagu E. I. (2025). N2 Neutrophils and Tumor Progression in Breast Cancer: Molecular Pathways and Implications. *Breast cancer (Dove Medical Press)*, *17*, 639–651. https://doi.org/10.2147/BCTT.S542787
4. Obeagu, E. I., &Obeagu, G. U. (2024). Exploring the profound link: Breastfeeding's impact on alleviating the burden of breast cancer - A review. *Medicine*, *103*(15), e37695. https://doi.org/10.1097/MD.0000000000037695

© 2025, IJCRCPS. All Rights Reserved

5. Berta, D. M., Teketelew, B. B., Chane, E., Bayleyegn, B., Tamir, M., Cherie, N., Seyoum, M., Mekuanint, A., &Aynalem, M. (2024). Hematological changes in women with cervical cancer before and after cancer treatment: retrospective cohort study. *Scientific reports*, *14*(1), 27630. https://doi.org/10.1038/s41598-024-75937-6
6. Obeagu, E. I., &Obeagu, G. U. (2024). Breast cancer: A review of risk factors and diagnosis. *Medicine*, *103*(3), e36905. https://doi.org/10.1097/MD.0000000000036905
7. Obeagu, E. I., &Obeagu, G. U. (2024). Exploring neutrophil functionality in breast cancer progression: A review. *Medicine*, *103*(13), e37654. https://doi.org/10.1097/MD.0000000000037654
8. Obeagu E. I. (2025). Anemia and hematocrit decline in cervical cancer: unveiling clinical consequences and management strategies. *Annals of medicine and surgery (2012)*, *87*(9), 5784–5791. https://doi.org/10.1097/MS9.0000000000003620
9. Powrózek, T., Dziwota, J., &Małecka-Massalska, T. (2021). Nutritional Deficiencies in Radiotherapy-Treated Head and Neck Cancer Patients. *Journal of clinical medicine*, *10*(4), 574. https://doi.org/10.3390/jcm10040574
10. Obeagu E. I. (2025). Neutrophil-driven tumor inflammation in breast cancer: Pathways and therapeutic implications: A narrative review. *Medicine*, *104*(25), e43024. https://doi.org/10.1097/MD.0000000000043024
11. Martins, C. D. S., &Maasdorp, S. D. (2023). Outcomes of patients with haematological malignancies and febrile neutropenia at the Universitas Academic Hospital multidisciplinary intensive care unit, Free State Province, South Africa. *African journal of thoracic and critical care medicine*, *29*(1), 10.7196/AJTCCM.2023.v29i1.263. https://doi.org/10.7196/AJTCCM.2023.v29i1.263
12. Campian, J. L., Sarai, G., Ye, X., Marur, S., & Grossman, S. A. (2014). Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. *Head & neck*, *36*(12), 1747–1753. https://doi.org/10.1002/hed.23535
13. Obeagu E. I. (2025). The selenium paradox friend or foe in breast cancer?.*Annals of medicine and surgery (2012)*, *87*(9), 5569–5577. https://doi.org/10.1097/MS9.0000000000003464
14. Loechl, C. U., Datta-Mitra, A., Fenlason, L., Green, R., Hackl, L., Itzkowitz, L., Koso-Thomas, M., Moorthy, D., Owino, V. O., Pachón, H., Stoffel, N., Zimmerman, M. B., &Raiten, D. J. (2023). Approaches to Address the Anemia Challenge. *The Journal of nutrition*, *153 Suppl 1*(Suppl 1), S42–S59. https://doi.org/10.1016/j.tjnut.2023.07.017
15. Berta, D. M., Teketelew, B. B., Chane, E., Bayleyegn, B., Tamir, M., Cherie, N., Seyoum, M., Mekuanint, A., &Aynalem, M. (2024). Hematological changes in women with cervical cancer before and after cancer treatment: retrospective cohort study. *Scientific reports*, *14*(1), 27630. https://doi.org/10.1038/s41598-024-75937-6
16. Obeagu E. I. (2025). The selenium paradox friend or foe in breast cancer?.*Annals of medicine and surgery (2012)*, *87*(9), 5569–5577. https://doi.org/10.1097/MS9.0000000000003464
17. Tsuda, N., Watari, H., & Ushijima, K. (2016). Chemotherapy and molecular targeting therapy for recurrent cervical cancer. *Chinese journal of cancer research = Chung-kuo yen cheng yen chiu*, *28*(2), 241–253. https://doi.org/10.21147/j.issn.1000-9604.2016.02.14
18. Regalado Porras, G. O., Chávez Nogueda, J., &PoitevinChacón, A. (2018). Chemotherapy and molecular therapy in cervical cancer. *Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of*

© 2025, IJCRCPS. All Rights Reserved

Radiation Oncology, *23*(6), 533–539. https://doi.org/10.1016/j.rpor.2018.09.002
19. Deng, B., Kong, W., Han, C., Zhou, C., Li, J., Song, D., & Lin, Y. (2024). Study of long-term effects of pelvic radiotherapy on the function of bone marrow in recurrent cervical cancer patients. *International journal of medical sciences*, *21*(10), 2000–2010. https://doi.org/10.7150/ijms.95900
20. Obeagu E. I. (2025). The nutritional equation: decoding diet's influence on breast cancer risk and progression - a perspective. *Annals of medicine and surgery (2012)*, *87*(9), 5528–5534. https://doi.org/10.1097/MS9.0000000000003612
21. Damen, P. J. J., Lin, S. H., & van Rossum, P. S. N. (2024). Editorial: Updates on radiation-induced lymphopenia. *Frontiers in oncology*, *14*, 1448658. https://doi.org/10.3389/fonc.2024.1448658
22. Prades-Sagarra, E., Yaromina, A., & Dubois, L. J. (2024). Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives. *Clinical and translational radiation oncology*, *49*, 100852. https://doi.org/10.1016/j.ctro.2024.100852
23. Ning, K., Sun, X., Liu, L., & He, L. (2024). Prevalence and contributing factors of anemia in patients with gynecological cancer: a retrospective cohort study. *Scientific reports*, *14*(1), 10628. https://doi.org/10.1038/s41598-024-61015-4
24. Berta, D. M., Teketelew, B. B., Chane, E., Bayleyegn, B., Tamir, M., Cherie, N., Seyoum, M., Mekuanint, A., &Aynalem, M. (2024). Hematological changes in women with cervical cancer before and after cancer treatment: retrospective cohort study. *Scientific reports*, *14*(1), 27630. https://doi.org/10.1038/s41598-024-75937-6
25. Obeagu, E. I., &MaibougeTanko, M. S. (2025). Iron metabolism in breast cancer: mechanisms and therapeutic implications: a narrative review. *Annals of medicine and surgery (2012)*, *87*(6), 3403–3409. https://doi.org/10.1097/MS9.0000000000003173
26. Lustberg M. B. (2012). Management of neutropenia in cancer patients. *Clinical advances in hematology &oncology : H&O*, *10*(12), 825–826.
27. Kubeček, O., Paterová, P., &Novosadová, M. (2021). Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. *Life (Basel, Switzerland)*, *11*(12), 1387. https://doi.org/10.3390/life11121387
28. Prades-Sagarra, E., Yaromina, A., & Dubois, L. J. (2024). Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives. *Clinical and translational radiation oncology*, *49*, 100852. https://doi.org/10.1016/j.ctro.2024.100852
29. Wang, X., Wang, P., Zhao, Z., Mao, Q., Yu, J., & Li, M. (2020). A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. *Therapeutic advances in medical oncology*, *12*, 1758835920926822. https://doi.org/10.1177/1758835920926822
30. Obeagu E. I. (2025). N2 Neutrophils and Tumor Progression in Breast Cancer: Molecular Pathways and Implications. *Breast cancer (Dove Medical Press)*, *17*, 639–651. https://doi.org/10.2147/BCTT.S542787
31. Gao, A., Zhang, L., & Zhong, D. (2023). Chemotherapy-induced thrombocytopenia: literature review. *Discover oncology*, *14*(1), 10. https://doi.org/10.1007/s12672-023-00616-3
32. Obeagu E. I. (2025). Thromboinflammatory pathways in breast cancer: clinical and molecular insights into venous thromboembolism risk - a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5822–5828. https://doi.org/10.1097/MS9.0000000000003644
33. Harrison, L., & Blackwell, K. (2004). Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?.*The oncologist*, *9 Suppl 5*, 31–40. https://doi.org/10.1634/theoncologist.9-90005-31

© 2025, IJCRCPS. All Rights Reserved

34. Clarke, R. T., Jenyon, T., van Hamel Parsons, V., & King, A. J. (2013). Neutropenic sepsis: management and complications. *Clinical medicine (London, England)*, *13*(2), 185–187. https://doi.org/10.7861/clinmedicine.13-2-185
35. Obeagu, E. I., &Obeagu, G. U. (2024). Predictive models and biomarkers for survival in stage III breast cancer: a review of clinical applications and future directions. *Annals of medicine and surgery (2012)*, *86*(10), 5980–5987. https://doi.org/10.1097/MS9.0000000000002517
36. Ménétrier-Caux, C., Ray-Coquard, I., Blay, J. Y., &Caux, C. (2019). Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?*Journal for immunotherapy of cancer*, *7*(1), 85. https://doi.org/10.1186/s40425-019-0549-5
37. Warny, M., Helby, J., Nordestgaard, B. G., Birgens, H., &Bojesen, S. E. (2018). Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. *PLoS medicine*, *15*(11), e1002685. https://doi.org/10.1371/journal.pmed.1002685
38. Ashworth, I., Thielemans, L., &Chevassut, T. (2022). Thrombocytopenia: the good, the bad and the ugly. *Clinical medicine (London, England)*, *22*(3), 214–217. https://doi.org/10.7861/clinmed.2022-0146
39. Nell, E. M., &Chapanduka, Z. C. (2022). Aetiology of pancytopenia: Experience of a South African tertiary academic centre. *African journal of laboratory medicine*, *11*(1), 1645. https://doi.org/10.4102/ajlm.v11i1.1645
40. Fetscher, S., &Mertelsmann, R. (2000). Supportive care in hematologic malignancies: hematopoietic growth factors, infections, transfusion therapy. *Current opinion in hematology*, *7*(4), 255–260. https://doi.org/10.1097/00062752-200007000-00009

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Haematology
DOI: 10.22192/ijcrcps.2025.12.09.002	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2025). Blood Counts and Beyond: Haematological Complications in Cervical Cancer Therapy. Int. J. Curr. Res. Chem. Pharm. Sci. 12(9): 44-51.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.09.002

© 2025, IJCRCPS. All Rights Reserved